In the context of limited healthcare budgets During the
2016 yellow fever outbreak in Angola and the Democratic Republic of the Congo, the WHO approved the use of fractional dose vaccination to deal with a potential shortage of vaccine. In August 2016, a large vaccination campaign in
Kinshasa used 1/5 of the standard vaccine dose. In 2018 it was reported that fractional dose vaccination with 1/5 of the standard vaccine dose, administered intradermally, conferred protection for 10 years, as documented by a randomized clinical trial. In
Poliomyelitis, fractional dose vaccination has been shown to be effective while reducing overall cost, rendering polio vaccination available to more individuals.
In the Covid-19 pandemic In a pandemic wave, fractional dose vaccination is considered to accelerate widespread access to vaccination when vaccine supply is limited: In the
COVID-19 pandemic,
epidemiologic models predict a major benefit of personalized fractional dose vaccination strategies with certain vaccines in terms of case load, deaths, and shortening of the pandemic.
To reduce side effects In some segments of the population, disease risk is lower but specific vaccine side effect risks may be increased. In such subpopulations, fractional dose vaccination might optimize the benefit-risk ratio of vaccination for an individuum and optimize the cost-benefit relation for society. == References ==